Results for Hematology & Oncology

Comprehensive myeloid assay available in 2020 to run on the Ion Torrent Genexus System
CARLSBAD, Calif., Dec. 5, 2019 / PRNewswire / -- Clinical researchers who take a traditional sequential approach to analyze myeloid malignancies, a highly heterogeneous group of disorders, face a major hurdle: a laborious and time-consuming workflow. To simplify and accelerate the genomic profiling process, Thermo Fisher Scientific announced that the Ion Torrent…

Industry leaders discussed why a social-centric approach is especially important in oncology, particularly as it relates to health systems, interactions with healthcare providers, and family support.

Ideally, all decisions about whether to operate in a patient with cancer would be simple and straightforward. But the reality is that many cases are complex.

A new Choosing Wisely list in hematology focused specifically on children recommends five tests or procedures that experts say should be avoided, with some exceptions.

Shared decision making is promoted to improve cancer care quality. Patients and clinicians may have different ideas about what constitutes a cancer care decision, which may limit the validity of self‐reported...

The oncology team must be prepared to help sort myths from facts when patients ask about the ketogenic diet, the alkaline diet, and fasting.

Early results from a trial of JAK inhibitors for hair loss will be unveiled at the upcoming dermatology meeting. Specialists will also delve into the adverse skin effects of immunotherapy.

Overview of the COPE program
As you get older, you want cancer care that looks at all of you – your medical conditions, living situation, medications, and other factors – while planning your care. There is one hospital focused specifically on the needs of older patients with cancer: Roger Williams Medical Center
We are home to the state’s first Geriatric Oncology Program, which we call COPE…

Question: How can I benefit from an oncology scial worker during or after my cancer treatment?

HOUSTON, Nov. 20, 2019 / PRNewswire / -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced Chief Executive Officer of CNS Pharmaceuticals, John M. Climaco, along with founder, Waldemar Priebe, PhD, and members of management, including, Chief Medical Officer, Sandra Silberman, MD, PhD, Chief Scientific Officer, Donald Picker, PhD, and scientific advisory board…

PrimeVax Immuno-Oncology, Inc. announced today its CEO, Tony Chen, will be presenting at the Annual Biocom Global Life Science Partnering Conference. The presentation will take place on March 2,...

SMi Group's 4th annual Immunogenicity conference and exhibition promises to establish a collaborative networking platform for industry, regulatory and academic experts to unite and engage in...

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Memorial Sloan Kettering Cancer Center (MSK), the world's oldest and largest private cancer center, today announced...

Immuno-oncology is the interaction between the immune system and cancerous cells, described by the three E’s of immunoediting; involving the elimination, equilibrium and escape stages. Discover antibodies available to key cells in the tumor microenvironment along with other resources for immuno-oncology research.

Learn more about applying for Lab Assistant - Hematology at LABORATORY CORP OF AMERICA HOLDINGS

Nektar Therapeutics (Nasdaq: NKTR) today announced five preclinical data presentations for its immuno-oncology programs made at the American Association for Cancer Research (AACR) Annual Meeting...